Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)

Summary

  • In the United States, adefovir is indicated for the treatment of compensated chronic HBV infection in patients aged 12 years or older (Table 3)[FDA Adefovir]
  • The European indication includes patients with decompensated liver disease[EMA Adefovir]
  • The risk of resistance with adefovir is lower than with lamivudine but high enough to preclude its use as a first-line agent

Action required